RegCell (Series A)
Funding Details
Awarder
Inbox
Date Award
September 18, 2026
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount
$44,000,000
Company Info
Founders
Professor Shimon Sakaguchi
Market
Autoimmune diseases
Location
Emeryville, CA, USA
Coinvestors
Alumni Ventures Group, Fast Track Initiative, Global Brain, Kyoto iCAP, LG Technology Ventures, Medical Incubator Japan, Mitsui Chemicals, OSAKA University Venture Capital, Playground Global, The University of Tokyo Edge Capital Partners
Company Description

RegCell is a global biotechnology company pioneering therapy for autoimmune diseases. Their proprietary immune tolerance platform is based on the Nobel Prize-winning research of Co-Founder Professor Shimon Sakaguchi and is built to generate stable, epigenetically reprogrammed, antigen-specific Tregs designed to restore immune tolerance.

Links
Website
Back to HomeBack to Biotechnology DealsView Funding Announcement